Neoadjuvant immunotherapy for resectable hepatocellular carcinoma – Authors' reply

Thomas U. Marron; Myron E. Schwartz; Elizabeth Miller; Pradeep Thanigaimani; Israel Lowy; Gavin Thurston; Miriam Merad

doi:10.1016/S2468-1253(22)00122-4

Neoadjuvant immunotherapy for resectable hepatocellular carcinoma – Authors' reply

Thomas U. Marron, Myron E. Schwartz, Elizabeth Miller, Pradeep Thanigaimani, Israel Lowy, Gavin Thurston, Miriam Merad

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	505
Number of pages	1
Journal	The Lancet Gastroenterology and Hepatology
Volume	7
Issue number	6
DOIs	https://doi.org/10.1016/S2468-1253(22)00122-4
State	Published - Jun 2022

Access to Document

10.1016/S2468-1253(22)00122-4

Cite this

@article{32cac3773ae34b2f83802912d1c6a17d,

title = "Neoadjuvant immunotherapy for resectable hepatocellular carcinoma – Authors' reply",

author = "Marron, {Thomas U.} and Schwartz, {Myron E.} and Elizabeth Miller and Pradeep Thanigaimani and Israel Lowy and Gavin Thurston and Miriam Merad",

note = "Funding Information: TUM has received research funding from Boehringer Ingelheim, Bristol Myers Squibb, Merck, and Regeneron Pharmaceuticals, and has served on advisory boards or data safety monitoring boards, or both, of AstraZeneca, Atara, Boehringer Ingelheim, Celldex, Chimeric Therapeutics, Genentech, Regeneron Pharmaceuticals, Riboscience, and the Rockefeller University. EM, IL, and GT are employees and shareholders of Regeneron Pharmaceuticals. PT reports stock ownership in Mannkind and is an employee and shareholder of Regeneron Pharmaceuticals.MM reports consulting roles with Asher Bio, Celsius Therapeutics, Compugen, Dren Bio, Genenta, Innate Pharma, Morphic Therapeutic, Myeloid Therapeutics, and Nirogy Therapeutics. MM also receives research funding from Boehringer Ingelheim, Genentech, Regeneron Pharmaceuticals, and Takeda; honoraria from Amgen and GSK; and reports ownership interest less than 5% in Asher Bio, Celsius Therapeutics, Compugen, Dren Bio, Genenta, Morphic Therapeutic, Myeloid Therapeutics, and Nirogy Therapeutics. MES declares no competing interests.",

year = "2022",

month = jun,

doi = "10.1016/S2468-1253(22)00122-4",

language = "English",

volume = "7",

pages = "505",

journal = "The Lancet Gastroenterology and Hepatology",

issn = "2468-1253",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - Neoadjuvant immunotherapy for resectable hepatocellular carcinoma – Authors' reply

AU - Marron, Thomas U.

AU - Schwartz, Myron E.

AU - Miller, Elizabeth

AU - Thanigaimani, Pradeep

AU - Lowy, Israel

AU - Thurston, Gavin

AU - Merad, Miriam

N1 - Funding Information: TUM has received research funding from Boehringer Ingelheim, Bristol Myers Squibb, Merck, and Regeneron Pharmaceuticals, and has served on advisory boards or data safety monitoring boards, or both, of AstraZeneca, Atara, Boehringer Ingelheim, Celldex, Chimeric Therapeutics, Genentech, Regeneron Pharmaceuticals, Riboscience, and the Rockefeller University. EM, IL, and GT are employees and shareholders of Regeneron Pharmaceuticals. PT reports stock ownership in Mannkind and is an employee and shareholder of Regeneron Pharmaceuticals.MM reports consulting roles with Asher Bio, Celsius Therapeutics, Compugen, Dren Bio, Genenta, Innate Pharma, Morphic Therapeutic, Myeloid Therapeutics, and Nirogy Therapeutics. MM also receives research funding from Boehringer Ingelheim, Genentech, Regeneron Pharmaceuticals, and Takeda; honoraria from Amgen and GSK; and reports ownership interest less than 5% in Asher Bio, Celsius Therapeutics, Compugen, Dren Bio, Genenta, Morphic Therapeutic, Myeloid Therapeutics, and Nirogy Therapeutics. MES declares no competing interests.

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85129762407&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(22)00122-4

DO - 10.1016/S2468-1253(22)00122-4

M3 - Letter

C2 - 35550051

AN - SCOPUS:85129762407

VL - 7

SP - 505

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

SN - 2468-1253

IS - 6

ER -